Fampyra™ is the commercial brand name of Fampridine Sustained‑release Tablets, an oral potassium‑channel blocker developed by Biogen. It blocks voltage‑gated potassium channels on demyelinated nerve fibres, enhances nerve impulse conduction, thus improving motor function in multiple‑sclerosis patients.
Main Indications
Improvement of walking ability in adult patients with multiple sclerosis.
Clinical Research
Global multicenter double‑blind, placebo‑controlled Phase‑III trials demonstrated that Fampyra™ can effectively increase walking speed among multiple‑sclerosis patients;
Clinical responses are usually observed within 2‑4 weeks after treatment initiation, and disappear within 2 weeks upon drug discontinuation;
Domestic multicenter clinical trials in China showed consistent efficacy and safety results between Chinese patients and global trial populations.
Common Side Effects
Serious risks: seizures, insomnia, renal function impairment;
Common mild adverse reactions: dizziness, headache, nausea, asthenia, back pain, balance disorder, paraesthesia and allergic reactions.
Approval Status in China
Original drug Fampyra™ (Fampridine Sustained‑release Tablets) was officially approved for marketing in China in 2021, with the specification of 10 mg. It is currently a prescription drug included in China’s category B medical insurance.
Buy Fampyra (Fampridine Sustained‑release Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
